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QT-prolonging drugs: Should they 
ever be used?
Andrzej Okreglicki (Dr AO) trained at Groote Schuur Hospital, Newcastle, UK, and Rochester, NY, USA. His main interests
are arrhythmias, interventional cardiology, rhythm devices and sudden cardiac arrest.
If the current stringent conditions of bodies that register and
control medicines had been in force for decades, many
commonly used drugs (from antibiotics and antihistamines to
antipsychotics and antiarrhythmics) would never have
reached the consumer market. Nowadays, pre-release
findings of QT prolongation are likely to scupper early-phase
trials and result in the abandonment of experimental drugs.
Post-marketing surveillance has identified a number of
commonly used drugs either as causing QT prolongation or
associated with increased sudden unexpected deaths.1
Thioridazine (see p. 46 of this issue) is such a drug.2,3
The QT interval in the ECG for most part represents the
electrical ‘recharging’ of the cardiac myocytes after their
depolarisation which initiates systole.  This interval is not a
passive resting period for the cells but an active, highly co-
ordinated orchestration of numerous transmembranous ion
channels that open and close in a specific sequence.  A
change in activity of these ion channels, due either to a
genetic defect resulting in a channelopathy or to ‘promiscuity’
of the ion channels in allowing various drugs and not only
ions to enter the channel, can lead to a marked slowing of
repolarisation particularly in the M-cells situated between the
epicardial and endocardial myocytes of the ventricular wall.4
Not only may the QT become prolonged but voltage
differences in the different layers of the heart may trigger
after-depolarisations, polymorphic ventricular tachycardia,
usually described as torsade de pointes, and even the total
chaotic rhythm of ventricular fibrillation, the lethal arrhythmia
that only defibrillation can reverse.  The side-effects of drugs
that interfere with ion channels may therefore present with
silent ECG abnormalities, palpitations, syncope or sudden
death. The study reported in this journal confirms that
thioridazine is a drug that can have a significant effect on the
ECG.2,5
Clearly, the best option would be to avoid all drugs that have
the potential for prolonging QT.  Unfortunately, this solution is
not always possible: the drugs may be highly effective in
treating the condition for which they are marketed, the drugs
may be the cheaper alternative, or there may be no similar
non-QT-lengthening drug available.  Furthermore, the
arrhythmic complications of the drugs may be rare and may
have been missed by pre-release testing and only identified
by careful post-marketing surveillance.
Can the side-effects of a QT-prolonging drug be predicted or
tested for?  ECG evidence of QT prolongation in an
individual exposed to the drug, especially if marked, should
rule out its use. (A QTc interval of > 500 ms is an arbitrarily
determined value and used as a marker of unacceptable
risk.) Unfortunately, the corollary of a QT below the upper
limit of normal does not indicate safety.  The QT is a very
variable interval on the ECG and is influenced by heart rate,
electrolytes, circulating catecholamine levels and even
smoking.  Drugs that have been shown in population studies
to lengthen the mean QT intervals compared with controls
may not significantly prolong the interval on random ECGs of
a vulnerable individual or prolong the QT beyond the
accepted normal upper limit, and yet still pose a risk of a
lethal arrhythmia. Normal physiological QT variability and
magnitudes of QT lengthening too small to be measured by
the standard ECG may mask the covert, potentially life-
threatening, electrophysiological effect of the drug. 
Conditions not tested for before the launch of the drugs may
increase susceptibility to such a drug.  Combination with
other agents that may alter metabolism or elimination of the
drug could result in marked elevation of drug concentration,
competitively blocking more vulnerable ion channels.
Various patient conditions that reduce the ‘recharging’ or
repolarisation reserve of cardiac myocytes increase the risk
of arrhythmias.  These conditions include heart failure and
electrolyte abnormalities such as hypokalaemia, which may
be the result of diuretic use, diarrhoea or bulimia.4,6
Interestingly, the finding that sudden death is more frequent
among psychiatric patients in general and among those on
antipsychotics in particular is not new.3
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One must be aware that while there are many drugs that may
prolong the QT, not all these drugs have been implicated
individually in causing any clinical arrhythmia.1 With these
drugs, reassurance of their safety comes from their extensive
use over many years and continuing, careful and transparent
post-release surveillance.  These drugs should, however, still
not be used in combination with other QT-prolonging drugs
or in vulnerable persons. 
Drugs that have been implicated in torsade de pointes and
lethal arrhythmias should preferably not be used. The ECG
has limited value in guiding their use.  Yes, it can show when
it is probably dangerous to use such drugs (when QT
prolongation occurs), but more importantly, even when
apparently normal it can never be interpreted as an
indication that their use is safe.  Justification for the use of
these drugs must be the outcome of a careful calculation of
risk versus benefit.  Thus, in cardiology, we may knowingly
prescribe antiarrhythmic agents with a potential of causing
torsade at a risk level 100-fold that of some psychiatric drugs
(2 - 4% for sotalol v. 1 in 10 000 for some antipsychotics),
when the alternative, off the drugs and untreated, is an even
higher risk of unsuppressed lethal arrhythmias.3,6,7 If a similar
benefit can be shown for non-cardiac, QT-prolonging and
torsade-implicated drugs, then their use can be condoned.  If
not, these drugs should be avoided.
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